BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31835809)

  • 21. Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies.
    Chatelut M; Harzer K; Christomanou H; Feunteun J; Pieraggi MT; Paton BC; Kishimoto Y; O'Brien JS; Basile JP; Thiers JC; Salvayre R; Levade T
    Clin Chim Acta; 1997 Jun; 262(1-2):61-76. PubMed ID: 9204210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel V97G ASAH1 mutation found in Farber disease patients: unique appearance of the disease with an intermediate severity, and marked early involvement of central and peripheral nervous system.
    Chedrawi AK; Al-Hassnan ZN; Al-Muhaizea M; Colak D; Al-Younes B; Albakheet A; Tulba S; Kaya N
    Brain Dev; 2012 May; 34(5):400-4. PubMed ID: 21893389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The molecular medicine of acid ceramidase.
    Frohbergh M; He X; Schuchman EH
    Biol Chem; 2015 Jun; 396(6-7):759-65. PubMed ID: 25938220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skin inflammation and impaired adipogenesis in a mouse model of acid ceramidase deficiency.
    Rybova J; Kuchar L; Sikora J; McKillop WM; Medin JA
    J Inherit Metab Dis; 2022 Nov; 45(6):1175-1190. PubMed ID: 36083604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy.
    Elsea SH; Solyom A; Martin K; Harmatz P; Mitchell J; Lampe C; Grant C; Selim L; Mungan NO; Guelbert N; Magnusson B; Sundberg E; Puri R; Kapoor S; Arslan N; DiRocco M; Zaki M; Ozen S; Mahmoud IG; Ehlert K; Hahn A; Gokcay G; Torcoletti M; Ferreira CR
    Hum Mutat; 2020 Sep; 41(9):1469-1487. PubMed ID: 32449975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceramidases, roles in sphingolipid metabolism and in health and disease.
    Coant N; Sakamoto W; Mao C; Hannun YA
    Adv Biol Regul; 2017 Jan; 63():122-131. PubMed ID: 27771292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acid Sphingomyelinase Inhibition in Stored Erythrocytes Reduces Transfusion-Associated Lung Inflammation.
    Hoehn RS; Jernigan PL; Japtok L; Chang AL; Midura EF; Caldwell CC; Kleuser B; Lentsch AB; Edwards MJ; Gulbins E; Pritts TA
    Ann Surg; 2017 Jan; 265(1):218-226. PubMed ID: 28009749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis for the activation of acid ceramidase.
    Gebai A; Gorelik A; Li Z; Illes K; Nagar B
    Nat Commun; 2018 Apr; 9(1):1621. PubMed ID: 29692406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Farber disease [Farber lipogranulomatosis], acid ceramidase deficiency].
    Koga M
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):389-93. PubMed ID: 9645089
    [No Abstract]   [Full Text] [Related]  

  • 30. Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency:the utility of animal models of disease in the toxicological evaluation of potential therapeutics.
    Murray JM; Thompson AM; Vitsky A; Hawes M; Chuang WL; Pacheco J; Wilson S; McPherson JM; Thurberg BL; Karey KP; Andrews L
    Mol Genet Metab; 2015 Feb; 114(2):217-25. PubMed ID: 25092414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Farber's lipogranulomatosis].
    Koga M
    Nihon Rinsho; 1995 Dec; 53(12):3009-13. PubMed ID: 8577050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Turnover of endogenous ceramide in cultured normal and Farber fibroblasts.
    van Echten-Deckert G; Klein A; Linke T; Heinemann T; Weisgerber J; Sandhoff K
    J Lipid Res; 1997 Dec; 38(12):2569-79. PubMed ID: 9458280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions.
    Kleynerman A; Rybova J; Faber ML; McKillop WM; Levade T; Medin JA
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acid ceramidase deficiency: Farber disease and SMA-PME.
    Yu FPS; Amintas S; Levade T; Medin JA
    Orphanet J Rare Dis; 2018 Jul; 13(1):121. PubMed ID: 30029679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs.
    Gulbins E; Palmada M; Reichel M; Lüth A; Böhmer C; Amato D; Müller CP; Tischbirek CH; Groemer TW; Tabatabai G; Becker KA; Tripal P; Staedtler S; Ackermann TF; van Brederode J; Alzheimer C; Weller M; Lang UE; Kleuser B; Grassmé H; Kornhuber J
    Nat Med; 2013 Jul; 19(7):934-8. PubMed ID: 23770692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells.
    Carpinteiro A; Edwards MJ; Hoffmann M; Kochs G; Gripp B; Weigang S; Adams C; Carpinteiro E; Gulbins A; Keitsch S; Sehl C; Soddemann M; Wilker B; Kamler M; Bertsch T; Lang KS; Patel S; Wilson GC; Walter S; Hengel H; Pöhlmann S; Lang PA; Kornhuber J; Becker KA; Ahmad SA; Fassbender K; Gulbins E
    Cell Rep Med; 2020 Nov; 1(8):100142. PubMed ID: 33163980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis.
    Becker KA; Riethmüller J; Lüth A; Döring G; Kleuser B; Gulbins E
    Am J Respir Cell Mol Biol; 2010 Jun; 42(6):716-24. PubMed ID: 19635928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acid sphingomyelinase mediates murine acute lung injury following transfusion of aged platelets.
    McVey MJ; Kim M; Tabuchi A; Srbely V; Japtok L; Arenz C; Rotstein O; Kleuser B; Semple JW; Kuebler WM
    Am J Physiol Lung Cell Mol Physiol; 2017 May; 312(5):L625-L637. PubMed ID: 28283474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis.
    Teichgräber V; Ulrich M; Endlich N; Riethmüller J; Wilker B; De Oliveira-Munding CC; van Heeckeren AM; Barr ML; von Kürthy G; Schmid KW; Weller M; Tümmler B; Lang F; Grassme H; Döring G; Gulbins E
    Nat Med; 2008 Apr; 14(4):382-91. PubMed ID: 18376404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease.
    Bedia C; Camacho L; Abad JL; Fabriàs G; Levade T
    J Lipid Res; 2010 Dec; 51(12):3542-7. PubMed ID: 20871013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.